We are pioneering the first ever CAR-neutrophil drug delivery platform – an elegant therapeutic approach that harnesses the innate infiltration power of neutrophils to deliver anti-cancer payloads directly into the heart of solid tumors.
Solid tumors remain one of the most difficult challenges in oncology. Despite breakthroughs in targeted therapies and immunotherapy, patient responses are often inconsistent, and relapse is common.
A major reason?Most drugs simply can’t get in.
The dense, chaotic architecture of solid tumors creates a multidimensional barrier that prevents therapies from penetrating deep into the tissue. It’s a simple truth: no matter how powerful a drug may be, it can’t work if it can’t reach the target.
…to treat the hardest to reach solid tumors.
A BIOLOGICAL OPPORTUNITY
Neutrophils As Drug Delivery Systems
Neutrophils are the most abundant cell of the innate immune system and harbor powerful – yet largely untapped – therapeutic properties.
Intriguingly , neutrophils are naturally equipped with traits ideal for therapeutic transport into solid tumors.
1. They’re phagocytic, meaning they can engulf and carry small particles (including drug-loaded nanoparticles).
2. They’re highly infiltrative, routinely recruited deep into solid tumors where other immune cells are excluded.
3. They reside in the deep tumor until their death, ensuring localized payload release.
We’re tackling the hardest to treat solid tumors.
CAR-NE: OUR ELEGANT SOLUTION
Drug-Loaded CAR-Neutrophils
Leveraging the natural drug delivery characteristics of neutrophils and the precision of advanced genetic engineering, we’ve developed an elegant cell therapy platform called CAR-NE.
CAR-NE is an allogeneic neutrophil cell therapy equipped with a chimeric antigen receptor (CAR) and loaded with potent therapeutic payloads. These cells are designed for one function: to deliver a knockout blow deep within solid tumors.